UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 62 filers reported holding UNIQURE NV in Q3 2015. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $36 | -12.2% | 1,834 | 0.0% | 0.00% | – |
| Q4 2022 | $41 | -100.0% | 1,834 | -94.3% | 0.00% | -100.0% |
| Q3 2022 | $607,000 | -64.6% | 32,384 | -64.8% | 0.00% | -66.7% |
| Q2 2022 | $1,715,000 | -13.3% | 91,998 | -16.0% | 0.01% | +12.5% |
| Q1 2022 | $1,978,000 | +760.0% | 109,473 | +884.4% | 0.01% | +700.0% |
| Q4 2021 | $230,000 | -87.0% | 11,121 | -80.0% | 0.00% | -85.7% |
| Q3 2021 | $1,774,000 | +1243.9% | 55,500 | +889.3% | 0.01% | +600.0% |
| Q1 2018 | $132,000 | -70.7% | 5,610 | -88.1% | 0.00% | -50.0% |
| Q3 2017 | $451,000 | -57.0% | 47,023 | -74.9% | 0.00% | -60.0% |
| Q4 2016 | $1,049,000 | +30.5% | 187,476 | +71.9% | 0.01% | +25.0% |
| Q2 2016 | $804,000 | -22.8% | 109,033 | +182.6% | 0.00% | -20.0% |
| Q2 2015 | $1,041,000 | +468.9% | 38,585 | +413.8% | 0.01% | +400.0% |
| Q1 2015 | $183,000 | +86.7% | 7,510 | +19.6% | 0.00% | 0.0% |
| Q1 2014 | $98,000 | – | 6,278 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |